Beijing Hotgen Biotech Co Ltd
SSE:688068
Beijing Hotgen Biotech Co Ltd
SSE:688068
Price:
28.44 CNY
1.68%
Market Closed
Updated:
Apr 29, 2024
Beijing Hotgen Biotech Co Ltd
Operating Income
|
Beijing Hotgen Biotech Co Ltd
Operating Income Peer Comparison
Comparables:
603259
300759
2269
300347
W
2268
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Beijing Hotgen Biotech Co Ltd
SSE:688068
|
Operating Income
¥1.1B
|
CAGR 3-Years
220%
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Operating Income
¥11.5B
|
CAGR 3-Years
52%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Operating Income
¥1.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Operating Income
¥4.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Operating Income
¥1.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
34%
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Operating Income
¥147.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Beijing Hotgen Biotech Co Ltd's Operating Income?
Operating Income
1.1B
CNY
1.1B
CNY
Based on the financial report for Dec 31, 2022, Beijing Hotgen Biotech Co Ltd's Operating Income amounts to 1.1B CNY.
What is Beijing Hotgen Biotech Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
102%
102%
Over the last year, the Operating Income growth was -57%. The average annual Operating Income growth rates for Beijing Hotgen Biotech Co Ltd have been 220% over the past three years , 102% over the past five years .
You don't have any saved screeners yet
